Oligodendroglioma

Overview


Tumour Group: Glioma
WHO Grade:

Can be classified as low-grade or high-grade.

An oligodendroglioma is considered Grade II; an anaplastic oligodendroglioma is Grade III.

Prevalence/Incidence: Oligodendrolglioma accounts for approximately 2.5% f all primary brain tumours and 5-6% of all gliomas. The incidence of oligodendroglioma has significantly increased over the past years.
Typical Age Range: This tumour type is more common among men and women in their 20s to 40s, but can occur in children.

Contents
Description of Tumour
Symptoms
Treatment / Standard of Care
Prognosis
References

Description of Tumour


Oligodendrogliomas come from oligodendrocytes, one of the types of cells that make up the supportive, or glial, tissue of the brain.

  • May be associated with 1p or 19q chromosomal losses
  • More common in men than women
  • Occurs frequently in the frontal or temporal lobes

Symptoms


Common symptoms include, but are not necessarily limited to:

  • Behavioural and cognitive changes
  • Headaches
  • Seizures
  • Weakness or paralysis

Treatment / Standard of Care


Treatment options depend on the grade of the tumour. If the tumour is low-grade and symptoms are not severe, the doctor may decide not to perform surgery, then “watch and wait” and evaluate tumour growth through MRIs.

There is a malignant form of this tumour called anaplastic oligodendroglioma and a mixed malignant astrocytoma-oligodendroglioma. The common treatment for these high-grade tumours is surgery followed by radiation therapy and/or chemotherapy.

Both low- and high-grade oligodendrogliomas can recur. If a tumour recurs, the doctor will evaluate it for a second surgical procedure, radiation, and/or chemotherapy.

Gene expression studies are used to classify gliomas based on certain characteristics or genetic profiles. Oligodendrogliomas can be identified by deficiencies in certain chromosomes named 1p and 19q. Genetic profiling of oligodendrogliomas provides a more accurate predictor of prognosis and treatment options than does standard pathology.

Prognosis  


A prognosis is an estimate of the likely progress of a disease after a diagnosis, based on an average patient group. Since every person is different, please take time to talk with your health care team about how this information applies to you.

By clicking on 'Expand,' a statistic on the prognosis for oligodendroglioma will be shown.

Expand for Prognosis Information

For brain tumour patients, a prognosis depends on several factors, which can include age and other health issues, the size of the tumour, its molecular profile, the type of tumour, how much can be removed and its response to treatments such as chemotherapy and radiation therapy.

Oligodendrogliomas are generally felt to be incurable using current treatments. However compared to the more common astrocytomas, they are slowly growing with prolonged survival. In one series, median survival times for oligodendrogliomas were 11.6 years for grade II and 3.5 years for grade III. However, such figures can be misleading since they do not factor in the types of treatment nor the genetic signature of the tumours.

Oligodendrogliomas, like all other infiltrating gliomas, have a very high (almost uniform) rate of recurrence and gradually increase in grade over time. Recurrent tumours are generally treated with more aggressive chemotherapy and radiation therapy. Recently, stereotactic surgery has proven successful in treating small tumours that have been diagnosed early.

References


Adult Brain Tumour Handbook 6th Edition. Brain Tumour Foundation of Canada. 2012.

"Oligodendroglioma" American Brain Tumour Association. American Brain Tumour Association, n.d. Web. July 4, 2013.

Oligodendroglioma. The National Brain Tumour Society, n.d. Web. July 4, 2013.

"Oligodendroglioma." Wikipedia. Wikimedia Foundation, 22 June 2013. Web. 4 July 2013.

Louis, David N. WHO Classification of Tumours of the Central Nervous System. Lyon: International Agency for Research on Cancer, 2007. Print

Image credited to RadsWiki (RadsWiki) [CC-BY-SA-3.0 (http://creativecommons.org/licenses/by-sa/3.0) or CC-BY-SA-3.0 (http://creativecommons.org/licenses/by-sa/3.0)], via Wikimedia Commons

 

You can also download this information as a Information Sheet on Oligodendroglioma (pdf).

 

 

With a busy, active life, a baby on the way and a blossoming career with the Winnipeg Police Service, Connor greeted September 27, 2011 worrying about a trip to the dentist. “The date just sticks in my mind,” he remembers. That fall day marked the beginning of Connor's journey with an oligodroglioma brain tumour. 

Read Connor's inspiring story >>

 

Share This

Featured Story

Courtney’s Story of Stability

Stability. It’s a strange concept when you have what it known to be a progressive, life long illness. You hear the words, “Your tumour growth is stable” and for a moment you think someone is playing the world’s worst prank on you.

Learn more

Spotlight

Stephen's Story: "I have faith that we will meet again"

Stephen and I chatted on what should have been his 32nd Wedding Anniversary. Stephen and Susan were married for 30 years and were best...

Learn more

Tommy's Story: Fellowship recipient

Dr. Tommy Alain, the very first research Fellow funded by Brain Tumour Foundation of Canada through the William Donald Nash Brain...

Learn more

Upcoming Events

  • 17/Jan/2018: Windsor Support Group: Meets at the United Way, Unit A1, 300 Giles Blvd. East... Learn more >
  • 17/Jan/2018: Calgary Support Group: Meets at Wellspring Calgary, 1404 Home Road NW, Calgary, Alberta, T3B 1G7... Learn more >
  • 17/Jan/2018: Niagara Region Support Group: Meets at Wellspring Niagara, 3250 Schmon Parkway, Thorold, ON, L2V 4Y6... Learn more >
  • 17/Jan/2018: Winnipeg Support Group: Sturgeon Creek United Church, 207 Thompson Drive, Winnipeg, MB... Learn more >
View All Events >
Thank you to the donors whose contributions make this website and all programs, services and research possible.

Copyright © 2018 Brain Tumour Foundation of Canada. Charitable Registration #BN118816339RR0001
35 Years